Plasma exchange prophylaxis has been shown to prevent disease recurrences in persons with mutation of CFH [Davin et al 2008]. Plasma exchange and eculizumab prophylaxis may prevent disease recurrences in those with mutation of circulating factors (CFH, C3, CFB, and CFI).
